Orchestra BioMed Secures $30 Million Strategic Agreement With Terumo for Virtue SAB Rights
Orchestra BioMed Holdings Inc. has entered into a $30 million strategic agreement with Terumo Corporation for the Virtue Sirolimus AngioInfusion Balloon (SAB) aimed at treating coronary artery disease. The deal includes a $10 million upfront payment and a $20 million investment in non-voting preferred stock. Terumo gains a right of first refusal for the global coronary indication of Virtue SAB, while Orchestra BioMed retains all development and distribution rights. The right of first refusal will last until 90 days after the primary endpoint data from the Virtue Trial is disclosed.
Orchestra BioMed Holdings Inc. announced new strategic agreements with Terumo Corporation regarding the Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of coronary artery disease. The new agreement grants Terumo a right of first refusal for the global coronary indication of Virtue SAB and supersedes the previous distribution agreement between the two companies. As part of the arrangement, Terumo will pay a total of $30 million to Orchestra BioMed, consisting of a $10 million upfront payment for the right of first refusal and a $20 million investment through a new series of non-voting preferred stock. Orchestra BioMed retains all development and distribution rights to Virtue SAB in all indications and has recently begun patient enrollment in its U.S. pivotal IDE trial for the treatment of coronary in-stent restenosis. The right of first refusal period will expire ninety days after the disclosure of the primary endpoint data from the Virtue Trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563207-en) on October 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
